Prostate cancer revealed by skin metastasis: A case report in black African man

AbstractIntroductionProstate cancer is the most common male malignancy in Togo. Most patients present with advanced and metastatic disease. Skin metastasis from prostate cancer is very rare and it occurs late and often with a poor prognosis. We report a case in a 52-year-old Togolese man where the skin lesions reveal the disease and with a good prognosis three years after treatment.ObservationIn 2012, a 52-year-old man presented in dermatology with multiple painless skin nodules on his chest. He did not have lower urinary tract symptoms The biopsy of the skin lesion (three nodules) showed a metastasis of adenocarcinoma type tumor and tumor markers performed pointed toward prostate as primary site. In urology a diagnostic biopsy (12 cores) of prostate revealed a high-grade (Gleason grade 4+4) adenocarcinoma. We performed a bilateral orchiectomy as androgen deprivation therapy and one month after this treatment the skin lesions have disappeared.ConclusionSkin metastasis of prostate cancer is rare and their recognition remains poor among practitioners requiring biopsy of the lesions. The prognosis could be better in newly diagnosed prostate cancer

Inheritance of Striga hermonthica adaptive traits in an earlymaturing white maize inbred line containing resistance genes from Zea diploperennis

Striga hermonthica can cause as high as 100% yield loss in maize depending on soil fertility level, type of genotype, severity of infestation and climatic conditions. Understanding the mode of inheritance of Striga resistance in maize is crucial for introgression of resistance genes into tropical germplasm and deployment of resistant varieties. This study examined the mode of inheritance of resistance to Striga in early‐maturing inbred line, TZdEI 352 containing resistance genes from Zea diploperennis. Six generations, P1, P2, F1, F2, BC1P1 and BC1P2 derived from a cross between resistant line, TZdEI 352 and susceptible line, TZdEI 425 were screened under artificial Striga infestation at Mokwa and Abuja, Nigeria, 2015. Additive‐dominance model was adequate in describing observed variations in the number of emerged Striga plants among the population; hence, digenic epistatic model was adopted for Striga damage. Dominance effects were higher than the additive effects for the number of emerged Striga plants at both locations signifying that non‐additive gene action conditioned inheritance of Striga resistance. Inbred TZdEI 352 could serve as invaluable parent for hybrid development in Striga endemic agro‐ecologies of sub‐Saharan Africa

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. Methods The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model—a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates—with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality—which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. Findings The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2–100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1–290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1–211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4–48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3–37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7–9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. Interpretation Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Imagerie multimodale dans le diagnostic d’un osteochondrome costal simulant une masse mammaire : un exemple de la complementarite des techniques irradiantes et non irradiantes.

Nous décrivons l’apport de l’imagerie médicale multimodale dans le diagnostic d’un cas d’ostéochondrome à localisation exceptionnelle costale mais retromammaire gauche, conférant un aspect de masse mammaire, chez une jeune fille de 17 ans, sans antécédent particulier. L’augmentation asymétrique du volume mammaire et la fermeté sans douleur du sein gauche, étaient le motif de consultation. L’imagerie basée sur la mammo-échographie, le scanner thoracique ont permis une orientation diagnostique. La certitude diagnostique est apportée par la biopsie de la lésion avec une étude cytohistologique. Ce cas illustre la complémentarité des techniques diagnostiques irradiantes et non irradiantes et dont la fusion en une imagerie hybride est à promouvoir.Mots clés: Mammographie, échographie, scanner, ostéochondrome, costale retromammaire

Ulcere de dieulafoy: une cause rare d’hemorragie digestive basse

L’ulcère de Dieulafoy est une cause rare d’hémorragie digestive en particulier l’hémorragie digestive basse. Nous rapportons dans cette observation un cas d’ulcère de Dieulafoy colique responsable d’une hémorragie digestive basse chez un sujet de 60 ans aux conditions de vie précaires, admis aux urgences de l’hôpital Saint-Louis de Paris. Le bilan initial comportant une rectosigmoidoscopie ainsi qu’une artériographie coeliomésentérique n’ayant pas permis de retrouver l’origine du saignement, une laparotomie exploratrice avec colectomie subtotale a été réalisée. L’examen histologique de la pièce opératoire avait montré au niveau de la paroi caecale une ulcération de la muqueuse et de la partie superficielle de la sous muqueuse, en regard d’une artère tortueuse et ectasique sous muqueuse, évoquant un ulcère de Dieulafoy. Cette observation illustre l’importance de l’examen histologique dans la prise en charge de cette lésion.Mots clés: Dieulafoy, hémorragie digestive basse, histopathologieEnglish Title: Dieulafoy disease: a rare cause of lower GI bleedingEnglish AbstractDieulafoy's ulcer is a rare cause of gastrointestinal bleeding in particular the lower gastrointestinal haemorrhage. We report in this observation a case of colonic Dieulafoy ulcer responsible for a lower gastrointestinal haemorrhage in a patient of 60 years, admitted to the emergency hospital of Saint Louis. Initial tests with arectosigmoidoscopy and a mesenteric arteriography laparoscopic did not reveal the source of bleeding, an exploratory laparotomy with subtotal colectomy was performed. Histological examination of the surgical specimen showed at the caecal wall an ulceration of the mucosa and superficial part of submucosa, associated with a tortuous and ectatic artery submucosa, suggesting a Dieulafoy ulcer. This case illustrates the importance of histology in the management of this lesion.Keywords: Dieulafoy, lower GI bleeding, histopatholog

Hernie de richter revelee par un abces inguinal droit

Objectifs : rapporter un cas de hernie de Richter de diagnostic difficile révélé par un abcès.Observation : Un cultivateur âgé de 40 ans sans antécédents particuliers avait été admis en consultation chirurgicale au CHR de Tsévié pour tuméfaction inguinale droite douloureuse évoluant depuis deux mois.L’examen avait révélée une tuméfaction douloureuse, luisante et infiltrant une paroi inflammatoire avec phénomène de peau d’orange ; non impulsive à la toux, irréductible. L’exploration chirurgicale sous anesthésie générale avait permis de drainer du pus, de noter une anse accolée à la paroi du sac et nécrosée à son sommet avec perforation du bord antimésentérique par incarcération latérale. Nous avions procédé àune résection d’iléon avec une anastomose immédiate. Une cure herniaire selon Bassini avait été pratiquée. Les suites opératoires ont été marquées par une suppuration pariétale.Conclusion : la hernie de Richter est une forme rare de diagnostic difficile à cause de sa symptomatologie atypique. Le retard de consultation  favorise le développement de phlegmon pyostercoral. Mots-clés : Hernie de Richter, étranglement, abcès. Richter hernia revealed by right inguinal abscess.Objectives: Report a difficult diagnose Richter hernia reveled by abcess.The 40 years old farmer was admitted at surgical department of regional hospital of Tsévié for inguinal abcess since two mounths. The exploration under general anesthesia fund pus, adherent necrosed small intestine. The intestinal resection was practiced and Bassini technic applied to the hernia. The postoperative consisted of wound suppuration.Conclusions: the Richter hernia is not frequent and it diagnose is difficult because of atypical symptoms. The late diagnose lead to abcess.Keys Words: Richter hernia, strangulation, abcess

Combining Ability of Extra-Early Maize Inbreds Derived from a Cross between Maize and Zea diploperennis and Hybrid Performance under Contrasting Environments

Knowledge of the genetic mechanisms conditioning drought tolerance in maize is crucial to the success of hybrid breeding programs aimed at developing high-yielding cultivars under drought. The objectives of this study were to determine the combining ability of extra-early inbreds, compute the heritability of measured traits, assess the performance of inbreds in hybrid combinations and investigate the associations among traits under drought and optimal conditions. A total of 252 hybrids generated by crossing 63 inbreds to four testers, along with four commercial hybrid checks, were evaluated for 2 years under drought and rainfed conditions. General combining ability (GCA) and specific combining ability (SCA) for the traits were significant. A total of 57.1% and 53.4% of the genotypic sum of squares were attributable to GCA effects for grain yield under managed drought and rainfed conditions, respectively. Hybrids TZdEEI 91 × TZEEI 21 and TZdEEI 55 × TZEEI 13 out-yielded the best checks under drought and optimal conditions by 49.13% and 39.05%, respectively. The most promising hybrids with consistently high grain yield under drought and rainfed conditions, were TZdEEI 54 × TZEEI 13, TZdEEI 91 × TZEEI 21 and TZdEEI 55 × TZEEI 21 and should be further evaluated for possible commercial production in sub-Saharan Africa

Orchi-épididymite tuberculeuse isolée : à propos d’un cas observé au CHU de Cocody, Abidjan (République de Côte d’Ivoire)

L’orchi-épididymite tuberculeuse isolée est une atteinte rare. Nous rapportons dans cette observation un cas chez un patient âgé de 62 ans présentant une douleur testiculaire avec masse scrotale droite d'allure tumorale. L'élimination d'un cancer testiculaire n'était pas possible sur les seules données échographiques. Une orchidectomie a été réalisée retrouvant à l'examen histopathologique un testicule détruit par plusieurs granulomes tuberculeux typiques avec fibrose emboutissant les tubes séminifères. Le traitement a consisté en une chimiothérapie antibacillaire avec évolution favorable. Cette observation illustre la nécessité d’évoquer l’orchi-épididymite tuberculeuse devant un testicule augmenté de taille chez un homme de région endémique et montre l'importance de l’anatomie pathologique dans la prise en charge pluridisciplinaire des patients.Mots clés : Orchi-épididymite, tuberculose, Anatomie pathologique.Isolated epididymo-orchitis is an uncommon presentation of tuberculosis. We report a case of 62 year-old patient with testicular pain and right scrotal mass-like tumor. The elimination of a testicular cancer was not possible on the only ultrasound data. An orchiectomy was done and the histopathological examination of specimen shown a testicle destroyed by several typical tuberculous granulomas with fibrosis stamping the seminiferous tubules. The treatment consisted of antibacillar chemotherapy with good evolution. This observation illustrates the need to think about tuberculous in case of an increased size testicle in endemic area, and shows the importance of pathology in the multidisciplinary care of patients.Keywords: Orchi-epididymitis, tuberculosis, pathology